Transparency, power, and influence in the pharmaceutical industry : policy gain or confidence game?

Introduction / Katherine Fierlbeck, Janice Graham, and Matthew Herder -- Transparency, Pharmaceuticals, and the Problem of Policy Change / Katherine Fierlbeck -- Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? / Courtney Davis, Shai Mulinari, and Tom Jefferson -- The FDA and Health Canada: Similar Origins, yet Divergent Paths and Approaches to Transparency / Margaret E. McCarthy and Joseph S. Ross -- Clinical Trial Data Transparency in Canada: Mapping the Progress from Laggard to Leader / Marc-André Gagnon, Matthew Herder, Janice Graham, Katherine Fierlbeck, and Anna Danyliuk -- The Limits of Transparency and the Role of Essential Medicines / Nav Persaud -- Speak No Secrets: (Non)transparency in Health Canada’s Communications about Pharmaceutical Regulation / Joel Lexchin -- The Political Economy of Influence: Ghost-Management in the Pharmaceutical Sector / Marc-André Gagnon -- Data Transparency and Rare Disease: Privacy versus Public Interest? / Kanksha Mahadevia Ghimire and Trudo Lemmens -- The European Registration of the Pandemic Influenza Vaccine Pandemrix: A Case Study of the Consequences of Poor Clinical Data Transparency / Tom Jefferson -- The Road Forward: How Researchers Can Sustain an Ethical and Transparent Health System / Rita Banzi -- Conclusion / Katherine Fierlbeck, Janice Graham, and Matthew Herder.